Emtricitabine Adjusted

Loading...

References

  1. Rajesh T Gandhi. Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel.. JAMA, 2025
  2. Joseph J Eron. Bictegravir/emtricitabine/tenofovir alafenamide in adults with HIV-1 and end-stage kidney disease on chronic haemodialysis.. HIV medicine, 2025
  3. Tom G. Jacobs. Lamivudine and Emtricitabine Dosing Proposal for Children with HIV and Chronic Kidney Disease, Supported by Physiologically Based Pharmacokinetic Modelling. Pharmaceutics, 2023
  4. Robin Schaefer. Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data.. The lancet. HIV, 2022
  5. J. Eron. Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.. The lancet. HIV, 2019
  6. E. Deeks. Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection. Drugs, 2018
  7. Elodie Valade. Population Pharmacokinetics of Emtricitabine in HIV-1-Infected Adult Patients. Antimicrobial Agents and Chemotherapy, 2014